Jubb et al. investigated DLL4 expression in metastatic breast cancer after VEGF treatment, and found anti-VEGF agents to be efficacious in treating DLL4-positive cancers [22] – suggesting DLL4 to be a good target for antiangiogenic therapies. The gene discussed is VEGFA; the disease is breast carcinoma.